EMMA — Emmaus Life Sciences, Inc.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 822370 ·
Last close
$0.01
Market Cap
$722.9K
52W High
$0.02
52W Low
$0.01
ADV30
63,110
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,982,000 | 1,814,000 | -823,000 | -3,335,000 | 18,696,000 | 1,072,000 | 86,556,000 |
| Dec 2025 | 3,852,000 | 3,617,000 | 886,000 | -1,951,000 | 21,436,000 | 2,127,000 | 85,044,000 |
| Sep 2025 | 3,378,000 | 3,131,000 | 695,000 | -2,076,000 | 20,756,000 | 293,000 | 80,244,000 |
| Jun 2025 | 2,817,000 | 2,667,000 | -370,000 | -1,135,000 | 23,344,000 | 886,000 | 79,045,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-634,000
Investing CF
$2,171,000
Financing CF
$-1,782,000
CapEx
$-6,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.14
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-273,402,000
Inventory
$1,909,000
Receivables
$2,048,000
ST Investments
—
EBIT TTM
$-484,000
Pretax Income TTM
$-8,488,000
Interest Exp TTM
$8,004,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 12,453,000 | 231,000 | -7,492,000 | 21,436,000 | 85,044,000 | — | -11,000 |
| Dec 2024 | 16,653,000 | -1,894,000 | -6,453,000 | 23,602,000 | 80,081,000 | — | -2,286,000 |
| Dec 2023 | 29,597,000 | 3,540,000 | -3,733,000 | 35,179,000 | 82,935,000 | — | -1,503,000 |
| Dec 2022 | 18,390,000 | -6,586,000 | -10,625,000 | 48,225,000 | 82,316,000 | — | -5,073,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.07
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OWPC | One World Products, Inc. | $600.5K | $0.00 | — |
| PTIX | Protagenic Therapeutics, Inc.\new | $905.1K | $0.50 | — |
| ATXI | AVENUE THERAPEUTICS, INC. | $1.05M | $0.32 | — |
| EVFM | Evofem Biosciences, Inc. | $1.06M | $0.01 | — |
| RGBPP | Regen BioPharma Inc | $1.06M | $0.01 | — |
News headlines (Yahoo Finance, 1h cache)
Emmaus Life Sciences Reports Quarterly Financial Results
2026-05-15 19:51 · Yahoo
Emmaus Life Sciences Reports Annual Financial Results
2026-03-31 02:00 · Yahoo
Emmaus, NIT sign Endari distribution agreement
2025-12-31 09:57 · Yahoo
Emmaus Life Sciences Announces Strategic Transaction
2025-12-30 21:30 · Yahoo
Emmaus Life Sciences Receives FDA Approval for Endari® Label Enhancements
2025-06-26 13:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.